Car-t cell therapy for refractory lupus nephritis
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called CD19 CAR-T cell therapy for people with severe lupus nephritis (lupus-related kidney inflammation) that hasn't improved with usual treatments. The therapy uses your own immune cells to target and possibly reset the immune system, which may reduce kidney damage and help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 65 with lupus (SLE) and a kidney biopsy showing active lupus nephritis (Classes III or IV).
- Your kidney function (eGFR) must be 30 or higher, and you must have significant protein in your urine (a sign of kidney damage).
- You must have tried standard lupus treatments that didn't work (refractory disease).
- Be willing to receive the experimental CAR-T cell therapy, which involves a blood draw (leukapheresis) and chemotherapy before the infusion.
- Have no active infections, no HIV, hepatitis, or tuberculosis, and no severe heart, liver, or blood problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
This trial tests a new treatment called ICG318 CAR-T, which uses your own immune cells to target and calm the overactive immune system in lupus. It may help people whose lupus has not improved with standard treatments, including those with lupus nephritis (kidney inflammation).
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
This trial tests a treatment called CART19, where your own immune cells are modified in a lab to target and destroy faulty B cells that cause lupus inflammation. It's for young people with active lupus that hasn't improved with standard treatments.
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.